Overview

Sildenafil and Outcome of IVF/ICSI Cycles

Status:
Unknown status
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
Adequate growth of the endometrium is crucial for implantation. Accordingly, the pregnancy success rate of patients with a thin endometrium is low. Furthermore, there is a little information about the factors responsible for impaired endometrial growth in patients with a thin endometrium. The researches have revealed that nitric oxide (NO) release can cause relaxation of vascular smooth muscle through a cyclic guanyl monophosphate (cGMP)-mediated pathway. Sildenafil is a type 5-specific Phosphodiesterase inhibitor that augments the vasodilatory effects of NO on vascular smooth muscle by preventing the degradation of cGMP and could improve blood flow and endometrial thickness. This study is designed to evaluate the effect of vaginally administered sildenafil suppositories on IVF/ICSI outcome of infertile patients with repeated IVF/ICSI failures.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Royan Institute
Collaborator:
Tehran University of Medical Sciences
Treatments:
Sildenafil Citrate